Biomarker Testing Services - Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) and Natural Killer cell (CAR-NK) therapies represent a groundbreaking advancement in cancer treatment. These therapies work by modifying a patient's immune cells, either T cells or NK cells, to produce receptors that specifically recognize and attack cancer cells. Once genetically engineered, these immune cells are reintroduced into the patient's body, where they seek out and destory cancer cells. CAR-T and CAR-NK therapies have shown particular promise in treating blood cencers such as leukemia and lymphoma.

However, while effective, these therapies can trigger severe side effects, particularly Cytokine Release Syndrome (CRS). CRS occurs when engineered immune cells release a flood of cytokines, which can cause dangerous inflammation. Additionally, patients may experience neurotoxicity, also known as Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can lead to confusion, seizures, and other neurological symptoms. Managing these risks requires careful study of CRS and neurotoxicity mechanisms to enhance both the safety and efficacy of cell therapies.

To monitor and mitigate these risks, testing for cytokine and neurotoxicity biomarkers in a patient’s blood is essential. Continuous biomarker monitoring helps researchers make informed decisions, ensuring that cell therapies are developed with high precision and safety.